Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

Autor: G. von Minckwitz, S. Loibl, M. Untch, H. Eidtmann, M. Rezai, P.A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, J. Huober, C. Solbach, C. Jackisch, G. Kunz, J.U. Blohmer, M. Hauschild, T. Fehm, V. Nekljudova, B. Gerber, K. Gnauert, B. Heinrich, T. Prätz, U. Groh, H. Tanzer, C. Villena, A. Tulusan, B. Liedtke, J.-U. Blohmer, C. Mau, J. Potenberg, J. Schilling, M. Just, E. Weiss, U. Bückner, M. Wolfgarten, R. Lorenz, G. Doering, S. Feidicker, P. Krabisch, U. Deichert, D. Augustin, K. Kast, C. Nestle-Krämling, C. Höß, J. Terhaag, P. Fasching, P. Staib, B. Aktas, T. Kühn, F. Khandan, V. Möbus, E. Stickeler, G. Heinrich, H. Wagner, A. Abdallah, T. Dewitz, G. Emons, A. Belau, V. Rethwisch, T. Lantzsch, C. Thomssen, U. Mattner, A. Nugent, V. Müller, T. Noesselt, F. Holms, T. Müller, J.-U. Deuker, D. Strumberg, C. Uleer, E. Solomayer, I. Runnebaum, H. Link, O. Tomé, H.-U. Ulmer, B. Conrad, G. Feisel-Schwickardi, C. Schumacher, T. Steinmetz, I. Bauerfeind, S. Kremers, D. Langanke, U. Kullmer, A. Ober, D. Fischer, A. Kohls, W. Weikel, J. Bischoff, K. Freese, M. Schmidt, W. Wiest, M. Sütterlin, M. Dietrich, M. Grießhammer, D.-M. Burgmann, B. Rack, C. Salat, D. Sattler, J. Tio, E. von Abel, B. Christensen, U. Burkamp, C.-H. Köhne, W. Meinerz, S.-T. Graßhoff, T. Decker, F. Overkamp, I. Thalmann, A. Sallmann, T. Beck, T. Reimer, G. Bartzke, M. Deryal, M. Weigel, P. Weder, C.-C. Steffens, S. Lemster, A. Stefek, F. Ruhland, M. Hofmann, J. Schuster, W. Simon, U. Kronawitter, M. Clemens, W. Janni, K. Latos, W. Bauer, A. Roßmann, L. Bauer, D. Lampe, V. Heyl, G. Hoffmann, F. Lorenz-Salehi, J. Hackmann, R. Schlag

Background The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane–based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd0d0889abbaa45ea11c291b5de85e20
https://www.ncbi.nlm.nih.gov/pubmed/25223482

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

Autor: von Minckwitz G; Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt. Electronic address: gunter.vonminckwitz@germanbreastgroup.de., Loibl S; Headquarter, German Breast Group, Neu-Isenburg., Untch M; Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin., Eidtmann H; Department of Gynaecology and Obstetrics, University Hospital, Kiel., Rezai M; Breast Center, Luisenkrankenhaus, Düsseldorf., Fasching PA; Department of Gynaecology and Obstetrics, University Hospital, Erlangen., Tesch H; Department of Medical Oncology, Chop GmbH, Frankfurt., Eggemann H; Department of Gynaecology and Obstetrics, University Hospital, Magdeburg., Schrader I; Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover., Kittel K; Department of Gynaecology and Obstetrics, Praxisklinik, Berlin., Hanusch C; Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München., Huober J; Department of Gynaecology and Obstetrics, University Hospital, Ulm., Solbach C; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt., Jackisch C; Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach., Kunz G; Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund., Blohmer JU; Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin., Hauschild M; Department of Gynaecology and Obstetrics, Hospital, Rheinfelden., Fehm T; Department of Gynaecology and Obstetrics, University Hospital, Tübingen., Nekljudova V; Headquarter, German Breast Group, Neu-Isenburg., Gerber B; Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany., Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2014 Dec; Vol. 25 (12), pp. 2363-2372. Date of Electronic Publication: 2014 Sep 15.